All filters
Slidesets
What is the place of the monoclonal antibodies in the clinic- Julià Blanco, PhD
Presented at:
European Meeting on HIV & Hepatitis 2018
Meeting
INTEREST 2018
Meeting
European HIV Clinical Forum 2017
Slidesets
State of the ART: Integrase Inhibitors Resistance- Charles Boucher, MD, PhD
Presented at:
European HIV Clinical Forum 2017
Slidesets
What is the virological support for reduced drug regimens?- Anne-Geneviève Marcelin, MD
Presented at:
European HIV Clinical Forum 2017
Slidesets
What is the clinical support for reduced drug regimens?- David Cooper, MD, DSc
Presented at:
European HIV Clinical Forum 2017
Slidesets
Real Life Experience of Dolutegravir and Lamivudine Dual Therapy as a Switching Regimen in HIV-TR Cohort.- D. Yağcı-Çağlayık
Presented at:
European HIV Clinical Forum 2017
Slidesets
Dolutegravir used in real-life provides high rates of virological response in conjunction with a rare emergence of integrase resistance.- D. Armenia
Presented at:
European HIV Clinical Forum 2017
Slidesets
French national survey of resistance to integrase inhibitors in a context of routine hospital care (ANRS AC11 Virology Network).- A.G. Marcelin
Presented at:
European HIV Clinical Forum 2017
Slidesets
Clinical case presentation- Christina Mussini, MD
Presented at:
European HIV Clinical Forum 2017
Slidesets
In-vitro selection of resistance mutations to dolutegravir outside HIV-1 integrase.- Dr. Olivier Delelis
Presented at:
European HIV Clinical Forum 2017
Slidesets
Genetic variability of HIV-2 LTR regions impacts transcriptional activities.- Q. Le Hingrat
Presented at:
European HIV Clinical Forum 2017
Slidesets
Serum cystatine as a marker for estimated glomerular filtration rate (eGFR) assessment in HIV-1-infected patients with dolutegravir-based antiretroviral therapy (ART).- R. Palich
Presented at:
European HIV Clinical Forum 2017
Slidesets
Clinical case presentation- Miłosz Parczewski, MD, PhD
Presented at:
European HIV Clinical Forum 2017
Slidesets
Evolution of bone mineral density and MDRD in HIV-infected patients treated with dolutegravir based regimens: results at 48- weeks- A. D'Avino
Presented at:
European HIV Clinical Forum 2017
Slidesets
Prospects of immunotherapy for treatment- Michael Lederman, MD
Presented at:
European HIV Clinical Forum 2017
Slidesets
One pill a day?: Integration novel delivery systems into routine care- Giovanni Di Perri, MD, PhD
Presented at:
European HIV Clinical Forum 2017
Slidesets
Understanding complexities of gut microbiome dysbiosis in HIV infected populations using a large cohor- Abigail Armstrong
Presented at:
International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2017
Slidesets
Differential responses of colonic ILCs to gut commensal bacteria altered during HIV infection- Moriah Castleman, PhD
Presented at:
International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2017
Slidesets
Milk - guiding the infant microbiome - Bruce German, PhD
Presented at:
International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2017
Slidesets
The microbial-derived short chain fatty acid butyrate directly and differentially inhibits gut T helper cell subset activation and proliferation- Jon Kibbie
Presented at:
International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2017
Slidesets
Opening Lecture: Brain-Gut-Microbiota interactions and intestinal health- Wendy Henderson, PhD, MSN, CRNP
Presented at:
International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2017
Slidesets
Role of the microbiome in HIV vaccine response heterogeneity- James Kublin, MD, MPH
Presented at:
International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2017